Back

Early empagliflozin initiation after hospitalization for heart failure in the United States: a target trial emulation

10 May 2026 (15:30 - 15:40)
Organised by: Logo
Congress Presentation Part of: Cardiorenal interactions and early therapeutic signals in acute heart failure Pharmacotherapy HFA Premium Access Heart Failure 2026 Heart Failure Association (HFA)

About the speaker

Photo
Professor Stephen Greene

Duke Clinical Research Institute, Durham (United States of America)

5 More presentations in this session

Presentation thumbnail
Timing matters: clinical outcomes of early sodium-glucose cotransporter-2 inhibitor initiation in acute heart failure
Doctor B. Resende (Coimbra, PT)
Abstract Slides Video
Presentation thumbnail
Clinical efficacy of sotagliflozin for heart failure outcomes across cardiac biomarker levels in SCORED
Doctor R. Aggarwal (Boston, US)
Abstract Slides Video
Presentation thumbnail
Efficacy and safety of finerenone in patients with cardio-kidney-metabolic syndrome and history of cancer: the FINE-HEART pooled analysis
Assistant Professor M. Ruppert (Boston, US)
Abstract Slides Video
Presentation thumbnail
Not all creatinine rises are kidney injury, early renal congestion phenotypes in acute heart failure
Mrs E. Vice (Atlanta, US)
Abstract Slides Video
Presentation thumbnail
Initiation of mineralocorticoid receptor antagonists in patients with cardiorenal diseases: potassium changes, hyperkalaemia risk and discontinuation in the CaRe study
Unknown S. Greene (Durham, US)
Abstract Slides Video

Access the full session

Session thumbnail
Cardiorenal interactions and early therapeutic signals in acute heart failure
Video

The Event

Event poster

Heart Failure 2026

10 May 2026 15:30 CET
You may be interested in
thumbnail
Congress Session
Cardiorenal interactions and early therapeutic signals in acute heart failure
thumbnail
Congress Presentation
The SGLT2 inhibitor empagliflozin in patients hospitalised for acute heart failure: a multinational randomised trial
thumbnail
Congress Presentation
Dapagliflozin in patients hospitalised with newly diagnosed heart failure: an analysis of the randomized DAPA ACT HF-TIMI 68 trial

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources